# Cefdinir Capsules 300 mg, Non-fasting

> **NCT00834535** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cefdinir Capsules 300 mg
- **DRUG:** OMNICEF® Capsule 300 mg

## Key facts

- **NCT ID:** NCT00834535
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00834535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00834535, "Cefdinir Capsules 300 mg, Non-fasting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00834535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*